Skip to main content

Table 2 Comparison of altered versus non-altered tumors

From: Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis

 

Alterations

No alterations

Gonadotroph

24

32

 Age

54.19 (14.1)

54 (14.1)

 Sex

  

  F

10 (41.7%)

11 (34.4%)

  M

14 (58.3%)

21 (65.6%)

 Recurrence

  

  Yes

15 (62.5%)

18 (56.3%)

  No

9 (37.5%)

14 (43.7%)

 Grade

  

  1a

7 (29.2%)

11 (34.4%)

  1b

1 (4.2%)

1 (3.1%)

 2a

12 (50.0%)

16 (50%)

  2b

4 (16.6%)

4 (12.5%)

 Size

  

  Microadenomas

0 (0%)

0 (0%)

  Macroadenomas

24 (100%)

31 (96.9%)

  Giant Adenomas

0 (0%)

1 (3.1%)

 Secretion

  

  Silent

24 (100%)

32 (100%)

  Functioning

0 (0%)

0 (0%)

Immunonegative

2

9

 Age

52.49 (7.5)

58.36 (11.6)

 Sex

  

  F

1 (50%)

3 (33.3%)

  M

1 (50%)

6 (66.7%)

 Recurrence

  

  Yes

1 (50%)

4 (44.4%)

  No

1 (50%)

5 (55.6%)

 Grade

  

  1a

0 (0%)

2 (22.2%)

  1b

0 (0%)

1 (11.1%)

  2a

2 (100%)

6 (66.7%)

  2b

0 (0%)

0 (0%)

 Size

  

  Microadenomas

0 (0%)

0 (0%)

  Macroadenomas

2 (100%)

8 (88.9%)

  Giant Adenomas

0 (0%)

1 (11.1%)

 Secretion

  

  Silent

2 (100%)

9 (100%)

  Functioning

0 (0%)

0 (0%)

Somatotroph

37

19

 Age

44.36 (12.9)

41.84 (10.8)

 Sex

  

  F

18 (48.7%)

12 (63.2%)

  M

19 (51.3%)

7 (36.8%)

 Recurrence

  

  Yes

23 (62.2%)

17 (89.5%)

  No

14 (37.8%)

2 (10.5%)

 Grade

  

  1a

12 (32.4%)

4 (21.1%)

  1b

2 (5.4%)

0 (0%)

  2a

16 (43.3%)

10 (52.6%)

  2b

7 (18.9%)

5 (26.3%)

 Size

  

  Microadenomas

3 (8.1%)

1 (5.6%)

  Macroadenomas

33 (89.2%)

17 (94.4%)

  Giant Adenomas

1 (2.7%)

0 (0%)

 GNAS

  

  WT

25 (67.6%)

15 (78.9%)

  Mutation

10 (27.0%)

3 (15.8%)

  Not available

2 (5.4%)

1 (5.3%)

 Secretion

  

  Silent

0 (0%)

4 (21.1%)

  Functioning

37 (100%)

15 (78.9%)

Lactrotroph

34

5

 Age

42.06 (14.7)

40.1 (6.9)

 Sex

  

  F

11 (32.4%)

2 (40.0%)

  M

23 (67.6%)

3 (60.0%)

 Recurrence

  

  Yes

27 (79.4%)

1 (20.0%)

  No

7 (20.6%)

4 (80.0%)

 Grade

  

  1a

9 (26.5%)

1 (20.0%)

  1b

2 (5.9%)

1 (20.0%)

  2a

12 (35.3%)

1 (20.0%)

  2b

11 (32.3%)

2 (40.0%)

 Size

  

  Microadenomas

1 (2.9%)

1 (20.0%)

  Macroadenomas

28 (82.4%)

4 (80.0%)

  Giant Adenomas

5 (14.7%)

0 (0.0%)

 Secretion

  

  Silent

2 (5.9%)

0 (0%)

  Functioning

32 (94.1%)

5 (100%)

Corticotroph

24

9

 Age

45.99 (12.0)

39.37 (18.7)

 Sex

  

  F

11 (45.8%)

5 (55.6%)

  M

13 (54.2%)

4 (44.4%)

 Recurrence

  

  Yes

13 (54.2%)

5 (55.6%)

  No

11 (45.8%)

4 (44.4%)

 Grade

  

  1a

12 (50.0%)

4 (44.5%)

  1b

1 (4.2%)

0 (0.0%)

  2a

11 (45.8%)

3 (33.3%)

  2b

0 (0%)

2 (22.2%)

 Size

  

  Microadenomas

5 (20.8%)

2 (22.2%)

  Macroadenomas

19 (79.2%)

7 (77.8%)

  Giant Adenomas

0 (0.0%)

0 (0.0%)

 Secretion

  

  Silent

5 (20.8%)

3 (33.3%)

  Functioning

19 (79.2%)

6 (66.7%)

 USP8

  

  WT

17 (70.8%)

5 (55.6%)

  Mutation

4 (16.7%)

1 (11.1%)

  Not available

3 (12.5%)

3 (33.3%)